Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice

Abstract

Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice, European Journal of Pharmacology, http://dx.doi.org/10.1016Pharmacology, http://dx.doi.org/10. /j.ejphar.2016 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. AbstractAsthma is a chronic respiratory disease characterized by airway inflammation, bronchoconstriction, airway hyperresponsiveness and recurring attacks of impaired breathing. Vasoactive intestinal peptide (VIP) has been proposed as a novel antiasthma drug due to its effects on airway smooth muscle relaxation, bronchodilation and vasodilation along with its immunomodulatory and anti-inflammatory properties. In the current study, we investigated the therapeutic effects of VIP when conjugated with α-alumina nanoparticle (α-AN) to prevent enzymatic degradation of VIP in the respiratory tract. VIP was conjugated with α-AN. Balb/c mice were sensitized and challenges with ovalbumin (OVA) or PBS and were divided in four groups; VIP-treated, α-AN-treated, α-AN-VIP-treated and beclomethasone-treated as a positive control group. Specific and total IgE level, airway hyperresponsiveness (AHR), bronchial cytokine expression and lung histology were measured. α-AN-VIP significantly reduced the number of 2 eosinophils (Eos), serum IgE level, Th2 cytokines and AHR. These effects of α-AN-VIP were more pronounced than that seen with beclomethasone or VIP alone (P<0.05). The current data indicate that α-AN-VIP can be considered as an effective nano-drug for the treatment of asthma.

Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases

“…Inhalation of VIP analogue Ro 25–1553 (a selective VPAC-2 receptor agonist) leads to a rapid bronchodilatory effect in asthmatic patients without any side effects [149]. Additionally, conjugated alpha-alumina nanoparticle with VIP has been proposed as an effective nano-drug for the treatment of asthma [150]. Additionally, induced expression of VIP and VIP associated receptors were reported in patients with atopic dermatitis [20, 129], allergic rhinitis [116] and EoE [63], suggesting the use of stable VIP antagonists or specific VIP receptors antagonist may be the logical approach for improving these inflammatory diseases.…”

Review on Swine Flu and Status of Swine Flu in Ethiopia

“…Athari SS, Pourpak Z, Folkerts G, Garssen J, Moin M, et al (2016) Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice. Eur…”

“…The asthma physiological hallmarks are air flow limitation and airway hyper responsiveness to broncho constrictor stimuli. The asthma standard therapy is potent antiinflammatory glucocorticoids and bronchodilation agents [1,2]. It is a chronic disease associated with immune system-biased inflammation.…”

Antimicrobial alumina nanobiostructures of disulfide- and triazole-linked peptides: Synthesis, characterization, membrane interactions and biological activity

“…Although the coupling of peptides to alumina nanoparticles seems to represent an excellent advantage in materials used as medical devices, little attention has been given to these promising nanobiomaterials. It was only recently shown that a peptide-alumina nanoparticle conjugate can be highly effective for the treatment of some biological conditions, such as allergic asthma in rats [14]. Very recently, our team proved the antimicrobial potential of nanofibrous alumina covalently bound to the antimicrobial peptide BP100 in assays against Escherichia coli and Salmonella typhimurium strains [15].…”